1. Home
  2. LEG vs PHVS Comparison

LEG vs PHVS Comparison

Compare LEG & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Leggett & Platt Incorporated

LEG

Leggett & Platt Incorporated

HOLD

Current Price

$11.75

Market Cap

1.6B

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$27.66

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LEG
PHVS
Founded
1883
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Home Furnishings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.7B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
LEG
PHVS
Price
$11.75
$27.66
Analyst Decision
Hold
Buy
Analyst Count
4
9
Target Price
$10.50
$39.44
AVG Volume (30 Days)
1.4M
205.4K
Earning Date
02-12-2026
11-12-2025
Dividend Yield
1.68%
N/A
EPS Growth
N/A
N/A
EPS
1.61
N/A
Revenue
$4,172,899,999.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$7.39
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.48
$11.51
52 Week High
$12.77
$29.80

Technical Indicators

Market Signals
Indicator
LEG
PHVS
Relative Strength Index (RSI) 49.36 57.92
Support Level $11.99 $26.73
Resistance Level $12.77 $28.20
Average True Range (ATR) 0.36 1.35
MACD -0.10 0.16
Stochastic Oscillator 10.09 76.69

Price Performance

Historical Comparison
LEG
PHVS

About LEG Leggett & Platt Incorporated

Leggett & Platt Inc designs and produces engineered components and products found in homes and automobiles. It operates its business through three segments namely Bedding Products, Specialized Products, and Furniture, Flooring, and Textile Products. It generates the majority of its revenue from Bedding Products. Serving a broad suite of customers around the world, Leggett & Platt's products include bedding components, automotive seat support, and lumbar systems, specialty bedding foam and private label finished mattresses, components for home furniture, and work furniture, flooring underlayment, adjustable beds, and various other products.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: